Should I buy Applied Therapeutics stock in 2025?

What is Applied Therapeutics?

How much is the Applied Therapeutics stock?

The price of Applied Therapeutics stock is falling this week. Currently trading at $0.3605, the stock has slipped by 4.40% over the last 24 hours and declined 12.05% across the week, with a total market capitalisation of $51.04 million.

The average daily trading volume over the past three months stands at 2.28 million shares. As the company remains unprofitable, there is no P/E ratio or dividend yield reported; its beta is high at 2.01, signalling significant price volatility compared to the wider market.

Given recent setbacks and pronounced fluctuations, investors in Ireland should approach Applied Therapeutics with caution and remain aware of high short-term risks.

Our full analysis on the Applied Therapeutics stock

Having meticulously reviewed Applied Therapeutics’ latest quarterly financials together with an in-depth analysis of its share price performance across the last three years, our evaluation integrates quantitative financial indicators, technical market signals, real-time trading data, and competitive context processed through our proprietary valuation models. This dynamic approach provides a holistic view of the firm as it navigates industry inflection points, regulatory challenges, and upcoming catalysts. So, why might Applied Therapeutics’ shares once again represent a compelling entry point into the biotech innovation space as 2025 unfolds?

Recent Performance and Market Context

Over the past twelve months, Applied Therapeutics (NASDAQ: APLT) has navigated an intense period of volatility, culminating in a sharp drawdown that contrasts with persistent innovation and long-term sector opportunities. As of 30 May 2025, APLT trades at $0.3605 per share, reflecting a significant contraction of 91.35% year-on-year and 82.24% over the last six months. While the latest weekly movement shows a decline of -12.05%, these compressed price levels are primarily the result of exogenous, event-driven selloffs rather than intrinsic strategic flaws.

Key negative events, including the FDA’s Complete Response Letter (CRL) for govorestat’s New Drug Application in classical galactosemia and a missed primary endpoint in the INSPIRE Phase 2/3 trial for SORD deficiency, precipitated most of the recent underperformance. Yet, these regulatory hurdles have reset expectations and compressed the stock to multi-year lows, setting the stage for a potential recalibration in investor sentiment.

From a broader perspective, the rare disease and central nervous system (CNS) treatment segment remains a highly favoured niche within biotech, underscored by robust M&A interest and continuing policy incentives in the US and EU for orphan drugs. Despite prevailing pessimism, secular demand for breakthrough treatments addressing rare metabolic disorders supports the sector’s medium- to long-term growth narrative. For Irish and European investors seeking high-conviction, asymmetric opportunities, such periods of compressed valuation frequently offer an appealing risk/reward reset.

Technical Analysis

A deep dive into Applied Therapeutics’ technical set-up reveals a landscape shaped by capitulation but now undergirded by notable structural support. All primary moving averages (20, 50, 100, and 200 days) trend above the current price, with the 200-day MA at $3.37, painting a picture of extended downside but also highlighting the potential scope for mean reversion.

• RSI (14 days): At 42.27, this sits in a neutral zone—neither overbought nor oversold—implying selling momentum has largely dissipated.
• MACD: The indicator is marginally positive at >-0.01, hinting at nascent bullish divergence.
• Support and Resistance: Extremely robust support is evident at $0.295 (52-week low). Short-term resistances cluster around $0.40–$0.43 (the 20- and 50-day MAs). A clear break above these reference points could trigger algorithmic buying and fund flows.

While the stock remains beneath all critical MAs, such technically depressed phases often precede substantial bottoming processes—particularly in small-cap biotech, where both retail and institutional flows can pivot rapidly on incremental news.

Fundamental Analysis

In terms of fundamentals, Applied Therapeutics is a development-stage biopharmaceutical innovator, with value levers distinct from traditional earnings-driven models. Q1 2025 results registered no commercial revenue (down from $190,000 in Q1 2024), and the company remains loss-making, posting a net loss of $21.8 million ($0.15 per share)—a modest outperformance relative to consensus expectations (-$0.16/share). Notably, the cash reserve remains sound at $50.8 million, providing flexibility to navigate clinical and regulatory timelines.

• Valuation: A $51 million market capitalisation reflects not only current challenges but also discounts future pipeline potential. The analyst consensus target of $6.10 signals that, even by conservative standards, the upside could be substantial if future catalysts materialise, with target price ranges extending from $1.50 to $14.
• Pipeline and Innovation: Applied Therapeutics has developed a differentiated pipeline targeting rare neurometabolic disorders—govorestat (AT-007), along with next-generation programs AT-001 and AT-003, underscores a platform approach with multiple shots on goal.
• Strategic Focus: The commitment to diseases with high unmet medical need (such as galactosaemia and peripheral neuropathies) positions APLT in a segment often rewarded by regulators and payors for clinical success, especially in the US and EU.

While the firm’s negative P/E and lack of current revenues are characteristic of high-growth biotech, structural strengths in IP, niche focus, and evidence of prudent financial management can serve as catalysts for valuation expansion post-infusion of positive data or regulatory clarity.

Volume and Liquidity

Market confidence is frequently reflected in sustained volume, and APLT’s daily trading average over the last 65 sessions sits at 2.28 million shares—a robust metric for a micro-cap US biotech.

• Shares Outstanding: 141.6 million shares, with a public float of 117.55 million shares, supports a healthy balance between liquidity and ownership concentration.
• Beta: At 2.01, APLT exhibits high volatility—attractive to traders and long-term specialised investors alike for its capacity to generate pronounced moves, especially as sentiment or clinical execution inflect.

In periods of transformative newsflow (for example, responses to FDA feedback or new partnership announcements), this kind of float structure can catalyse rapid price discovery, enhancing the appeal of timing entries at or near major support zones.

Catalysts and Positive Outlook

Applied Therapeutics enters the second half of 2025 armed with several near-term and medium-term catalysts capable of reversing sentiment and driving fast re-rating:

• Regulatory Response: The company’s anticipated reply to the FDA’s CRL for govorestat, and efforts to define an accelerated pathway for CMT-SORD deficiency, could quickly re-ignite expectations.
• Data Readouts: Comprehensive 12-, 18-, and 24-month data from the INSPIRE trial are expected to provide valuable insight into efficacy, durability, and safety—powerful drivers of revaluation.
• Strategic Positioning: The rare disease segment continues to benefit from expedited review and regulatory incentives, increasing the likelihood that strong data or effective stakeholder engagement may translate swiftly into commercial opportunity.
• Innovation: The company’s ongoing platform advances and capacity to pivot program resources increase its adaptability—an essential trait as the regulatory landscape evolves.

Added to the above, the broader biotech sector is attracting renewed investor interest in 2025, invigorated by favourable policy, robust dealmaking, and greater clarity around accelerated approval pathways in rare and orphan diseases.

Investment Strategies

Given the confluence of low absolute price, high volatility, and an approaching event calendar, several strategic entry points emerge for different investor profiles:

• Short-Term:
• Appealing for tactical traders seeking to benefit from volatility and sharp mean reversion moves off historic lows such as $0.295.
• Channel breakout above $0.40–$0.43 (technical resistances) could spark pronounced upside.
• Medium-Term:
• Positioning ahead of regulatory announcements or major data presentations enables exposure to sizeable event-driven upside.
• Scaling in at current technical lows provides optionality if catalysts surprise positively.
• Long-Term:
• For patient capital, the current market capitalisation discounts future pipeline potential far more aggressively than peers, offering significant convexity if any programme achieves regulatory or commercial inflection.
• The sector’s long-term structural trends remain intact, and successful navigation of current obstacles may transform sentiment and valuation multiple.

In all cases, prudent risk management and position sizing are paramount—a paradigm well understood by savvy biotech investors, especially in cases of regulatory complexity and cash runway considerations.

Is It the Right Time to Buy Applied Therapeutics?

In sum, Applied Therapeutics presents a compelling picture of deep value within the innovative biotech sphere. Key strengths include a robust and diversified pipeline, significant cash reserves relative to market capitalisation, and a business model tightly aligned with accelerating medical and regulatory trends targeting rare CNS and metabolic diseases. Technical momentum appears to be stabilising after a fundamental reset, with major support established and event-driven catalysts on the near-term horizon.

With the sector at an inflection point and a confluence of positive structural drivers emerging, Applied Therapeutics shares seem to represent an excellent opportunity for investors willing to look beyond near-term volatility and focus on medium- to long-term potential. As the company moves towards key regulatory responses and pipeline milestones, the risk/reward profile justifies serious renewed interest from growth-oriented and specialist investors alike.

For those seeking exposure to transformational biotech innovation at an asymmetric entry price, Applied Therapeutics offers a unique position—poised for a potential new bullish phase as 2025 progresses and key catalysts come into focus.

How to buy Applied Therapeutics stock in Ireland?

Buying Applied Therapeutics (APLT) stock online is both straightforward and secure when you use a regulated broker in Ireland. Investors typically have two main choices: spot buying, where you acquire actual shares, and CFD trading, where you speculate on the share price without holding the underlying asset. Each method caters to different investment profiles and goals. Both approaches can be accessed easily through leading online brokers. To help you decide, you’ll find a comprehensive broker comparison further down the page.

Spot buying (Cash purchase)

Cash buying involves purchasing real shares of Applied Therapeutics that you will then own directly in your brokerage account. With this method, you benefit from any rise in the share price and may participate in shareholder rights if applicable. Typical fees usually include a fixed commission per order, often ranging from €2 to €10 (for example, around $5 or €5 per trade).

Practical example

If Applied Therapeutics shares are priced at $0.36 each, with a $1,000 investment and a $5 brokerage fee, you can buy approximately 2,764 shares ($1,000 – $5 = $995; $995/$0.36 ≈ 2,764 shares).
✔️ Gain scenario: If the share price increases by 10%, your shares would be worth $1,100.
Result: That’s a $100 gross gain, or +10% on your initial investment.

Trading via CFD

CFD (Contract for Difference) trading lets you speculate on the movement of Applied Therapeutics’ share price without owning the shares directly. CFDs are popular for their flexibility, allowing both rising and falling markets and the use of leverage. Main costs include the spread (the broker’s markup on the share price) and overnight financing fees for leveraged positions held over multiple days.

Practical example

If you open a CFD position on Applied Therapeutics with $1,000 and use 5x leverage, your market exposure is $5,000.
✔️ Gain scenario: If APLT’s share price climbs by 8%, your leveraged position returns 8% × 5 = 40%.
Result: This could net you a $400 gain on your initial $1,000 margin (excluding fees).

Final advice

Before buying Applied Therapeutics stock, make sure to compare brokers’ fees, available platforms, and trading conditions, as these can significantly impact your returns. The right method—cash buying or CFD trading—depends on your objectives, risk appetite, and investment horizon. For a clear overview of the best providers for Irish investors, consult the broker comparison available further down the page. Happy investing!

Our 7 tips for buying Applied Therapeutics stock

The latest news about Applied Therapeutics

Applied Therapeutics’ Q1 2025 net loss was slightly better than analysts’ consensus expectations. In the most recent quarterly results released in May 2025, Applied Therapeutics reported a net loss of $21.8 million, or $0.15 per share, marginally outperforming the street’s expectation of a $0.16 per share loss. While revenues dropped to zero from $190,000 in the comparable period last year, this performance signals the company’s ability to manage costs somewhat more effectively than anticipated — a constructive albeit modest sign, especially as the company navigates a challenging operational environment.

The company retains a cash position of $50.8 million, supporting short-term development plans without immediate need for additional fundraising. As of March 31, 2025, Applied Therapeutics reported a cash balance of $50.8 million, down from $79.4 million at the end of 2024. While this burn rate is significant, the available cash provides the company with several months of operational runway. For Irish investors and institutions evaluating U.S.-listed development-stage biotech stocks, the presence of tangible liquidity is a key indicator of project continuity — thereby reducing short-term dilution or insolvency risk.

Upcoming regulatory responses and clinical data readouts remain the primary catalysts for stock performance. Applied Therapeutics’ management and investor communications emphasize pivotal events on the horizon, particularly the company’s response to the U.S. FDA’s Complete Response Letter (CRL) for its lead candidate, govorestat, in classic galactosemia, as well as forthcoming 12-, 18-, and 24-month data from the INSPIRE SORD deficiency trial. Success in these regulatory or clinical milestones could reinvigorate investor sentiment and generate renewed institutional interest from European and Irish healthcare-focused funds.

The analyst consensus price target for APLT remains substantially above current trading levels, highlighting potential upside if clinical or regulatory catalysts are positive. Despite the recent share price collapse, consensus analyst price targets average $6.10 (range $1.50–$14.00), which is more than fifteen times above the current trading price. For professional investors in Ireland, this wide gap underscores both the exceptionally high risk and the possibility of asymmetric returns, should Applied Therapeutics achieve regulatory breakthroughs or deliver unexpectedly positive trial updates.

Technical indicators offer mixed signals, with short-term momentum (MACD) turning mildly positive even as overall trend remains weak. Key technical indicators as of May 30 suggest a generally neutral to negative backdrop: the RSI stands at 42.27 (neutral), while all major moving averages are above the current share price, signaling continued weakness. However, the MACD (>–0.01) has recently flashed a buy signal, which could appeal to traders seeking short-term rebounds. For sophisticated Irish investors employing technical overlays as part of their biotech screening, this may indicate potential entry points aligned to speculative strategies, particularly as catalyst events approach.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.